Lifebit’s Post

Fantastic session on: "Innovations in addressing clinical needs" during Life Science Start-up Summit BRIC ILS. The panel constituted academician, practicing physicians, industry and regulatory experts. The brainstorming session had the following take-away messages: point-of-care diagnostics, affordable healthcare both for urban and rural settings, continued clinical collaboration and meticulous experimental documentation for regulatory clearances are key areas to focus when addressing clinical innovations. DBT ILS BioincubatorNivedita JenaBalaravi RavindranXCyton Diagnostics Private LimitedGauri MisraSai Praveen Haranath

📅 Save the Date for Patient Community Day! 🌍 Join us on 20 September 2024 for a groundbreaking event dedicated to patients and caregivers affected by MS, NMOSD, MOGAD, and related neurological conditions. Whether you're joining us in Copenhagen or tuning in online, this is an opportunity you won’t want to miss! 🔗 Register Here: https://bit.ly/3SQkJYR 🔊 Hear from Prof. Paola Zaratin from the Italian MS Society - AISM - as she highlights the importance of this event. As she puts it: “Patient Day organised by ECTRIMS is an important event to progress the size of patient engagement through scientific debate. And this is an important activity to promote patient engagement, to fill gaps between patients and the rest of stakeholders.” What to Expect? ✨ Insightful Talks: Learn from experts about the latest in MS, NMOSD, MOGAD, and more ✨ Interactive Q&A: Share your questions with leading specialists ✨ Global Access: Translations in 50+ languages, making this event accessible to all. 💬 Register now to secure your spot and be part of a global conversation that bridges the gap between patients, researchers and healthcare providers. #ECTRIMS4me #MS #NMOSD #MOGAD #PatientEngagement #PathwaysToCures

The star of the show isT.J. Sharpe and the reality of why we are still having this exhaustive conversation... is because of courageous humans like you and bewildered humans like me! Thank you so very much for changing my focus when I heard you speak for the first time almost 9 years ago. There is simply no more appropriate perspective than the lived human clinical trial participant and healthcare human experience in demonstrating the WHY NOT!! Informed decision making requires a commitment to ensuring the timely sharing of linked health data generated by patients/study participants wherever they are on their care journey and helps all stakeholders understand the patient experience, the evolution of patient safety, product effectiveness over time and valuable evidence generation. Solutions to ensure a risk-based, meaningful, pro-active, ethical approaches/options for the return of individual participant data and lay summaries demonstrates reciprocity, respect and partnership, requires global harmonization and flexibility and has the ability to transform the cultural thinking about what is possible when we critically think and re-think about our shared mutual objectives, reducing burden on health systems and patients to accelerate medicines development. Essential to ensuring the sustainability of R&D and improving global health equity. Providing pragmatic personalized options which matter most to patients and their care providers and securing mechanisms that will facilitate the convergence of clinical care and clinical research is no longer an option. #DIA2024 Session #373 Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard (MRCT Center) Innovative Health Initiative (IHI) Facilitate Project TransCelerate BioPharma Inc. Society for Clinical Research Sites (SCRS) CISCRP #pfdd #CRACO #Collaborating with #patients to enable a healthier future for all. Enabling #innovation and #equity ambitions through co-creation and global collaboration. #datasharing #patientsaspartners #healthinformation #bioethics

Terrific analysis and recommendations here -- excited to see how the ARPA-H Advancing Clinical Trial Readiness project and ARPANET-H will drive innovation, attract further investment, and help raise these scores #clinicalresearch #clinicaltrials #equitymatters

Mark your calendars for the highly anticipated virtual global summit on May 1st where key industry leaders across the globe will share in an open panel discussion the proposed recommendations to address the economic and operational gaps limiting the advancement of precision medicine. In 2023, a multi-stakeholder Forum was established to urgently address the specific economic gaps limiting the advancement of precision testing as identified in Diaceutics’ widely cited Clinical Practice Gaps paper published JCO in 2022. Sarah Hersey, Vice President and Head of Precision Medicine at Bristol-Myers Squibb and Forum member expressed: "This forum will serve as a healthy discourse to address the root complexities surrounding precision medicine and economic barriers. Together, the precision medicine community can identify possible solutions to close the clinical care gaps and help increase access to effective treatments for patients in need." Attendees will have the opportunity to contribute to a white paper of recommendations for industry and policy makers, playing a critical role in shaping the future of precision medicine. Register for free today: https://lnkd.in/edPcGVNX #PrecisionMedicine #HealthcareInnovation

SporeData's post on Bayesian adaptive designs in clinical trials underscores the importance of adaptive designs in improving the efficiency and ethical aspects of clinical research. Adaptive designs offer a flexible alternative to traditional fixed designs, allowing for modifications based on interim results without compromising the study's integrity. This methodology can lead to more effective and safer clinical trials, emphasizing patient safety and resource optimization. #BayesianAdaptiveDesigns #ClinicalTrialsInnovation #EfficientResearch #HealthcareDataScience #PatientSafetyEnhancement #collaboratewithsporedata

🖋 Register for our upcoming on-demand webinar "Unlocking New Frontiers: Pioneering Rare Indication Trials with AI-powered Study Feasibility".   🔈 Listen in as Industry experts Rohit Nambisan, Otis Johnson, PhD, MPA, Mohammed Ali, and Michelle Everill discuss some of the market trends driving more rare indication trials and the need for more complex feasibility in the study planning process.   🧠 Whether you're a researcher, clinician, or industry professional, this webinar will offer you valuable perspectives on the future of rare disease research and how AI-driven study feasibility is poised to revolutionize this complex landscape.    Secure your spot today 🚀 https://lnkd.in/gG-Qwtgi    #Clinicaltrials #raredisease #clinicalresearch #causalAI

🔬 There is just two days left until our webinar! Join us for "3 strategies for RWD challenges in clinical research and trials" on April 25th from 16:00 to 17:00 (BST). In our series focused on realising precision medicine, this session will delve into the exchange of perspectives regarding the critical role of real-world data (RWD) in clinical research and trials. Featuring industry experts Eric McDavid, RWD & Technology at Lifebit and Philip Awadalla, PhD, National Scientific Director at Canadian Partnership for Tomorrow's Health | Le partenariat canadien pour la santé de demain , learn about how RWD, derived beyond clinical trial settings, supports conventional research and trials. The topics of conversation for this webinar will include ensuring RWD security, navigating regulations and enabling secure access. Secure your spot now for insightful talks, discussions and Q&As: https://bit.ly/4b0A9Ab #PrecisionMedicine #RealWorldData #RWD #ClinicalResearch #ClinicalTrials #LifebitWebinars #Lifebit

This post showcases the advantages of #Bayesian adaptive designs in clinical trials, emphasizing their efficiency in reducing sample size and study duration, and enhancing patient safety through early stopping for futility. Drawing from the OSCAR trial case study, the post contrasts traditional trial methodologies with Bayesian adaptive approaches, highlighting the flexibility and efficiency of the latter. For a deeper understanding, refer to the original paper: https://lnkd.in/deKYU-dv. This comparison underscores the potential of Bayesian adaptive designs to streamline clinical research, making it a valuable read for professionals in the field. At SporeData Inc., our team possesses specialized expertise in designing Bayesian adaptive trials, offering tailored solutions that enhance the efficiency and effectiveness of clinical research. To learn more about Bayesian adaptive designs and how you can use them for your research, please contact SporeData Inc. Ricardo Pietrobon Lucas Teixeira Aline Machiavelli #BayesianAdaptiveDesigns #ClinicalTrialsInnovation #EfficientResearch #HealthcareDataScience #PatientSafetyEnhancement #collaboratewithsporedata

🌟 Honored For Our Oral Presentation at Chest Conference 2024 in Boston, USA! 🌟 I'm thrilled to announce that our original research was presented at the Chest Conference 2024, titled "Association of the Severity of Organophosphorus Compound Poisoning with Serum Amylase and Acetylcholinesterase Levels: An Observational Cross-Sectional Study." Our study analyzed 97 cases of acute Organophosphorus Compound (OPC) poisoning and showed the crucial role of serum amylase and acetylcholinesterase in assessing poisoning severity. We found significant correlations between these biochemical markers and clinical outcomes, underscoring their importance in managing OPC poisoning, especially in resource-limited settings. A big thank you to my amazing co-authors, including Darshankumar Raval, Krunal Gamit, Jignesh Vasava, Llai Barai, Gayatri Laha, Bhavana Nerella, Rohit Chandra Dey, and Vaishnavi Rathod for their contributions! Excited to continue contributing to the field of disaster medicine and patient care. You can read the full abstract here, https://lnkd.in/dQDcDbJY #ChestConference2024 #Boston #Research #DisasterMedicine #Organophosphorus #CriticalCare #MedicalResearch #Healthcare #MedicalScience #PatientCare